Last reviewed · How we verify
Rifapentine and Isoniazid for 3 months — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rifapentine and Isoniazid for 3 months (Rifapentine and Isoniazid for 3 months) — Taichung Veterans General Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rifapentine and Isoniazid for 3 months TARGET | Rifapentine and Isoniazid for 3 months | Taichung Veterans General Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rifapentine and Isoniazid for 3 months CI watch — RSS
- Rifapentine and Isoniazid for 3 months CI watch — Atom
- Rifapentine and Isoniazid for 3 months CI watch — JSON
- Rifapentine and Isoniazid for 3 months alone — RSS
Cite this brief
Drug Landscape (2026). Rifapentine and Isoniazid for 3 months — Competitive Intelligence Brief. https://druglandscape.com/ci/rifapentine-and-isoniazid-for-3-months. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab